Which of the following regimens is NOT a first‑line choice for hypertension: A) resistant hypertension – spironolactone; B) uncomplicated hypertension – angiotensin‑converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB) plus calcium‑channel blocker (CCB) or diuretic; C) hypertension with coronary artery disease – ACE inhibitor or ARB plus beta‑blocker; D) hypertension with heart failure – ACE inhibitor or ARB plus beta‑blocker plus diuretic; E) hypertension with chronic kidney disease – ACE inhibitor or ARB plus centrally acting agent?

Option E is NOT a first-line choice for hypertension with CKD

Centrally acting agents (such as clonidine or methyldopa) are not recommended as first-line therapy for hypertension with chronic kidney disease. The correct first-line approach for hypertensive patients with CKD is an ACE inhibitor or ARB, typically combined with a thiazide-like diuretic or calcium channel blocker—not a centrally acting agent 1.

Analysis of Each Option

Option A: Resistant Hypertension + Spironolactone ✓ CORRECT

• Spironolactone is the recommended fourth-line agent for resistant hypertension 2, 3, 4
• Multiple guidelines explicitly endorse spironolactone (25-50 mg/day) as the preferred add-on therapy when BP remains uncontrolled on triple therapy (ACE inhibitor/ARB + CCB + diuretic) 2, 3
• The PATHWAY-2 trial demonstrated spironolactone's superiority over doxazosin and bisoprolol in resistant hypertension 5
• FDA-approved indication for hypertension as add-on therapy 4

Option B: Uncomplicated Hypertension + ACE inhibitor/ARB + CCB or Diuretic ✓ CORRECT

• This represents standard first-line therapy for uncomplicated hypertension 1
• Guidelines consistently recommend thiazide/thiazide-like diuretics, long-acting CCBs, ACE inhibitors (in non-black patients), or ARBs as initial monotherapy 1
• Combination therapy with these agents is explicitly recommended when monotherapy fails 1, 6

Option C: Hypertension + CAD + ACE inhibitor/ARB + Beta-blocker ✓ CORRECT

• ACE inhibitors or ARBs are recommended for most patients with hypertension and coronary artery disease 7
• Beta-blockers are preferred as initial therapy for patients with stable angina 7
• This combination addresses both BP control and cardioprotection in CAD patients

Option D: Hypertension + Heart Failure + ACE inhibitor/ARB + Beta-blocker + Diuretic ✓ CORRECT

• This triple combination is the cornerstone of heart failure management 7, 3
• For systolic dysfunction (EF <40%), ACE inhibitors and beta-blockers are both Grade A recommendations 7
• Diuretics are essential for volume management in heart failure
• Mineralocorticoid receptor antagonists may be added for additional benefit 7, 3

Option E: Hypertension + CKD + ACE inhibitor/ARB + Centrally Acting Agent ✗ INCORRECT

• Centrally acting agents are NOT first-line therapy for any form of uncomplicated hypertension 1, 6, 1
• Guidelines explicitly state that centrally acting agents may only be used when BP remains uncontrolled with combinations of first-line agents, or when there are adverse effects 1, 8, 1
• For CKD patients, the correct first-line approach is ACE inhibitor or ARB combined with a thiazide-like diuretic or CCB—not a centrally acting agent 1
• Centrally acting agents are relegated to third-line or later therapy after failure of standard combinations 1, 9

Key Clinical Pitfalls

Common mistake: Assuming any combination with an ACE inhibitor/ARB is appropriate for CKD. The second agent matters—centrally acting drugs lack the evidence base and guideline support for first-line use in any population, including CKD patients.

Important distinction: While centrally acting agents (clonidine, methyldopa) may eventually be used in resistant hypertension after exhausting first-line options, they are never the initial add-on choice for any specific comorbidity, including CKD 1, 9.